GlycA (Nuclear Magnetic Resonance) integrates acute-phase glycoproteins; along with cluster of differentiation 163 (sCD163) and calprotectin, it outperforms high-sensitivity C-reactive protein (hs-CRP) for low-grade inflammation and predicts metabolic syndrome and coronary calcification. The gene discussed is CRP; the disease is metabolic syndrome.